Troxerutin protects against diabetic cardiomyopathy through NF-κB/AKT/IRS1 in a rat model of type 2 diabetes

Molecular Medicine Reports

Volumn 15, Issue 6, 2017, Pages 3473-3478

  Yu, Yongzhi ^a   Zheng, Guanzhong ^a  

^a The Affiliated Linzi District People's Hospital of Binzhou Medical University   (China)

Author keywords

AKT; Cardiomyopathy; Insulin receptor substrate 1; Nuclear factor B; Troxerutin; Type 2 diabetes

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; TROXERUTIN; BIOLOGICAL MARKER; INSULIN RECEPTOR SUBSTRATE; MONOXERUTIN; PROTEIN KINASE B;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIABETOGENESIS; GLUCOSE BLOOD LEVEL; HEART RATE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RAT; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; HYDROXYETHYLRUTOSIDE; INSULIN RECEPTOR SUBSTRATE PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85019626153     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2017.6456     Document Type: Article

References (28)

1. Fukuda T, Fukui M, Tanaka M, Senmaru T, Iwase H, Yamazaki M, Aoi W, Inui T, Nakamura N and Marunaka Y: Effect of Brazilian green propolis in patients with type 2 diabetes: A double-blind randomized placebo-controlled study. Biomed Rep 3:355-360, 2015.
2. Han L, Tang L, Wang C, Chen Z, Zhang T, Chen S, Liu S, Peng X, Mai Y and Duan S: Fat mass and obesity-associated gene rs11642015 polymorphism is significantly associated with prediabetes and type 2 diabetes subsequent to adjustment for body mass index. Biomed Rep 2:681-686, 2014.
3. Staimez LR, Weber MB, Narayan KM and Oza-Frank R: A systematic review of overweight, obesity, and type 2 diabetes among Asian American subgroups. Curr Diabetes Rev 9:312-331, 2013.
4. Yamada Y, Matsui K, Takeuchi I, Oguri M and Fujimaki T: Association of genetic variants of the α-kinase 1 gene with type 2 diabetes mellitus in a longitudinal population-based genetic epidemiological study. Biomed Rep 3:347-354, 2015.
5. Knabl J, Hüttenbrenner R, Hutter S, Günthner-Biller M, Riedel C, Hiden U, Kainer F, Desoye G and Jeschke U: Gestational diabetes mellitus upregulates vitamin D receptor in extravillous trophoblasts and fetoplacental endothelial cells. Reprod Sci 22:358-366, 2015.
6. Nicolucci A, Cercone S, Chiriatti A, Muscas F and Gensini G: A Randomized trial on home telemonitoring for the management of metabolic and cardiovascular risk in patients with type 2 diabetes. Diabetes Technol Ther 17:563-570, 2015.
7. Gu Y, Warren J, Walker N and Kennelly J: Gender differences in cardiovascular disease risk management for Pacific Islanders in primary care. Qual Prim Care 21:275-285, 2013.
8. Saisho Y: Glycemic variability and oxidative stress: A link between diabetes and cardiovascular disease? Int J Mol Sci 15:18381-18406, 2014.
9. Geetha R, Radika MK, Priyadarshini E, Bhavani K and Anuradha CV: Troxerutin reverses fibrotic changes in the myocardium of high-fat high-fructose diet-fed mice. Mol Cell Biochem 407:263-279, 2015.
10. Lu J, Wu DM, Zheng YL, Hu B, Cheng W, Zhang ZF and Li MQ: Troxerutin counteracts domoic acid-induced memory deficits in mice by inhibiting CCA AT/enhancer binding protein β-mediated inflammatory response and oxidative stress. J Immunol 190:3466-3479, 2013.
11. Schmeck-Lindenau HJ, Naser-Hijazi B, Becker EW, Henneicke-von Zepelin HH and Schnitker J: Safety aspects of a coumarin-troxerutin combination regarding liver function in a double-blind placebo-controlled study. Int J Clin Pharmacol Ther 41:193-199, 2003.
12. Zhang ZF, Shan Q, Zhuang J, Zhang YQ, Wang X, Fan SH, Lu J, Wu DM, Hu B and Zheng YL: Troxerutin inhibits 2, 2', 4, 4'-tetrabromodiphenyl ether (BDE-47)-induced hepatocyte apoptosis by restoring proteasome function. Toxicol Lett 233:246-257, 2015.
13. Yu X, Zhang Q, Cui W, Zeng Z, Yang W, Zhang C, Zhao H, Gao W, Wang X and Luo D: Low molecular weight fucoidan alleviates cardiac dysfunction in diabetic Goto-Kakizaki rats by reducing oxidative stress and cardiomyocyte apoptosis. J Diabetes Res 2014:420929, 2014.
14. Patel BM, Raghunathan S and Porwal U: Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. Eur J Pharmacol 728:128-134, 2014.
15. Stolen TO, Høydal MA, Kemi OJ, Catalucci D, Ceci M, Aasum E, Larsen T, Rolim N, Condorelli G, Smith GL and Wisløff U: Interval training normalizes cardiomyocyte function, diastolic Ca2+ control and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res 105:527-536, 2009.
16. Tan HW, Xing SS, Bi XP, Li L, Gong HP, Zhong M, Zhang Y and Zhang W: Felodipine attenuates vascular inflammation in a fructose-induced rat model of metabolic syndrome via the inhibition of NF-kappaB activation. Acta Pharmacol Sin 29:1051-1059, 2008.
17. Asare Y, Shagdarsuren E, Schmid JA, Tilstam PV, Grommes J, El Bounkari O, Schütz AK, Weber C, De Winther M P, Noels H and Bernhagen J: Endothelial CSN5 impairs NF-κB activation and monocyte adhesion to endothelial cells and is highly expressed in human atherosclerotic lesions. Thromb Haemost 110:141-152, 2013.
18. Hattori Y, Suzuki K, Tomizawa A, Hirama N, Okayasu T, Hattori S, Satoh H, Akimoto K and Kasai K: Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res 81:133-139, 2009.
19. Wang H, Bei Y, Lu Y, Sun W, Liu Q, Wang Y, Cao Y, Chen P, Xiao J and Kong X: Exercise prevents cardiac injury and improves mitochondrial biogenesis in advanced diabetic cardiomyopathy with PGC-1α and Akt activation. Cell Physiol Biochem 35:2159-2168, 2015.
20. Yu W, Wu J, Cai F, Xiang J, Zha W, Fan D, Guo S, Ming Z and Liu C: Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 7:e52013, 2012.
21. Lu Z, Ballou LM, Jiang Y P, Cohen IS and Lin RZ: Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-i. J Cardiovasc Pharmacol 58:439-445, 2011.
22. Lu J, Wu DM, Hu B, Zheng YL, Zhang ZF and Wang YJ: NGF-Dependent activation of TrkA pathway: A mechanism for the neuroprotective effect of troxerutin in D-galactose-treated mice. Brain Pathol 20:952-965, 2010.
23. Lakshmanan AP, Harima M, Sukumaran V, Soetikno V, Thandavarayan RA, Suzuki K, Kodama M, Nagata M, Takagi R and Watanabe K: Modulation of AT-1R/AMPK-MAPK cascade plays crucial role for the pathogenesis of diabetic cardiomyopathy in transgenic type 2 diabetic (Spontaneous Diabetic Torii) rats. Biochem Pharmacol 83:653-660, 2012.
24. Reinking BE, Wedemeyer EW, Weiss RM, Segar JL and Scholz TD: Cardiomyopathy in offspring of diabetic rats is associated with activation of the MAPK and apoptotic pathways. Cardiovasc Diabetol 8:43, 2009.
25. Gonzalez AB, Young L, Doll JA, Morgan GM, Crawford SE and Plunkett BA: Elevated neonatal insulin-like growth factor I is associated with fetal hypertrophic cardiomyopathy in diabetic women. Am J Obstet Gynecol 211:290e1-e7, 2014.
26. Sampath S and Karundevi B: Effect of troxerutin on insulin signaling molecules in the gastrocnemius muscle of high fat and sucrose-induced type-2 diabetic adult male rat. Mol Cell Biochem 395:11-27, 2014.
27. Pan Y, Wang Y, Zhao Y, Peng K, Li W, Wang Y, Zhang J, Zhou S, Liu Q, Li X, et al: Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose-induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 63:3497-3511, 2014.
28. Kuo WW, Wang WJ, Tsai CY, Way CL, Hsu HH and Chen LM: Diallyl trisufide (DATS) suppresses high glucose-induced cardiomyocyte apoptosis by inhibiting JNK/NFκB signaling via attenuating ROS generation. Int J Cardiol 168:270-280, 2013.